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Leucine-rich repeat kinase 2nt in the ubiquitin proteasome system (UPS) in Parkinson's disease (PD) is
mounting and becoming increasingly more convincing. However, it is presently unclear whether UPS
dysfunction is a cause or result of PD pathology, a crucial distinction which impedes both the understanding
of disease pathogenesis and the development of effectual therapeutic approaches. Recent ﬁndings discussed
within this review offer new insight and provide direction for future research to conclusively resolve this
debate.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionThe evidence for impairment in the ubiquitin proteasome system
(UPS) in Parkinson's disease (PD) is mounting and becoming
increasingly more convincing. However, it is presently unclear
whether UPS dysfunction is a cause or result of PD pathology, a
crucial distinction which impedes both the understanding of disease
pathogenesis and the development of effectual therapeutic
approaches. Thus recent ﬁndings speciﬁcally regarding the role of
the UPS in PD are discussed within this review, and offer new insight
and provide direction for future research to conclusively resolve this
debate.2. Parkinson's disease (PD)
PD is a progressive neurodegenerative disease clinically character-
ized by bradykinesia, gait disturbances, resting tremor, muscular
rigidity, and postural instability [1]. Pathological hallmarks of the
disease include loss of dopaminergic neurons in the substantia nigra
(SN), as well as the presence of eosinophilic cytoplasmic inclusions
and dystrophic neurites in remaining neurons, ﬁrst described by
Friederich Heinrich Lewy in 1912 and termed Lewy bodies (LB) and
Lewy neurites (LN) in his honor [2]. The identiﬁcation of α-synuclein
as the major, ﬁlamentous protein component of LBs [3], in addition to+1 904 953 7370.
rucelli).
ll rights reserved.the linkage of missense mutations (A53T, A30P, E46K) and genomic
duplication and triplication of the α-synuclein gene with autosomal
dominant PD [4–8], is indicative of a key role for α-synuclein in
disease pathogenesis. However, the detection of LBs in clinically
normal individuals upon postmortem analysis, frequently called
incidental Lewy body disease (iLBD), brings into question the
pathological signiﬁcance of α-synuclein aggregation. Utilizing a
unique brain donation program to control for the inherent biases
associated with more conventional case control studies, a recent
population-based study estimates the prevalence of synuclein
pathology in people over 70 years of age is approximately 37%, with
synuclein burden a poor predictor of clinical status/diagnosis [9].
Despite these ﬁndings, Dickson and colleagues demonstrate that iLBD
cases exhibit a decrement in tyrosine hydroxylase, a marker of
dopaminergic and noradrenergic neurons and a characteristic feature
of PD, in both striatal and epicardial nerve ﬁbers that is intermediate
to control and PD patients [10]. The authors conclude that the absence
of parkinsonian symptoms is the result of a subthreshold-level of
pathology, thus further solidifying the pathogenic role of α-synuclein
in PD progression.3. Ubiquitin proteasome system (UPS)
The UPS regulates the degradation of key regulatory proteins that
control signal transduction, cell cycle progression, apoptosis, as well as
cellular differentiation [11]. In addition to involvement in these
processes, the UPS also degrades misfolded and damaged proteins,
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including neurodegenerative diseases, cancer, inﬂammation, and
autoimmunity [12,13]. Given the detrimental consequences of
unregulated protein degradation, the UPS utilizes a class of enzymes
to covalently link ubiquitin polypeptide chains to proteins, marking
those proteins as substrates for the proteasome and allowing for
targeted and selective degradation (reviewed in [14,15]). Initially, the
carboxyl end of ubiquitin is activated in an ATP-dependent process by
the ubiquitin-activating enzyme (E1), which results in a highly
reactive ubiquitin thiolester that is transferred to a ubiquitin-carrier
protein (E2). The E3 class of enzymes, which are also called ubiquitin
protein ligases, recognize and bind proteins to be marked for
degradation, subsequently catalyzing the transfer of ubiquitin chains
from the E2 to lysine residues on protein substrates, which can serve
as a signal for proteasome-mediated degradation.
The proteasome is a large, multisubunit complex containing a
common proteolytic core, the 20S proteasome, which is composed of
28 subunits arranged in four, heptameric rings (reviewed in [15,16].
The two outer rings are each composed of seven alpha-type subunits
(α1–α7), while the two inner rings each contain seven beta-type
subunits (β1–β7). The proteolytic activity is enclosedwithin the inner
rings, with only β1, β2, and β5 subunits possessing caspase-like,
trypsin-like, and chymotrypsin-like cleavage speciﬁcity, respectively
[17,18]. These active sites have been shown to allosterically regulate
one another through substrate binding or cleavage, leading to a
proposed model in which single polypeptide chains are successively
hydrolyzed by a structured and coordinated activation of these
catalytic subunits [19,20]. However, Liu and colleagues present
evidence that a disordered polypeptide loop, such as a β-hairpin
structure, can also be permitted entry into the inner canal of the 20S
proteasome, allowing for the endoproteolytic cleavage and partial
degradation of unstructured proteins that is not dependent upon
ubiquitination [21]. This describes a novel function of the proteasome,
liberating active peptides from precursor proteins, as well as
correcting folding defects in internal domains of large proteins.
The activity of the 20S proteasome is modulated by a variety of
regulators, including the 19S/PA700 complex, PA200, as well as PA28
α/β and PA28γ [22–24]. The most common regulator, the 19S/PA700
complex, contains six AAA-family ATPases and is capable of binding
both ends of the 20S proteasome in an ATP-dependent manner,
forming the 26S proteasome, which is involved in the degradation of
ubiquitinated proteins [20,25,26]. Given that only the 19S/PA700
complex possesses ATPase activity and binds to polyubiquitin chains,
alternative regulators of the 20S proteasome are believed to modulate
ubiquitin-independent functions of the proteasome. However, hybrid
proteasomes have also been described, in which the 19S/PA700 and
PA28α/β complexes bind opposite ends of the 20S proteasome [27].
The speciﬁc function of these hybrid proteolytic complexes is unclear,
and studies evaluating the cellular localization of the 20S proteasome,
which has been detected in both nuclear and cytosolic compartments,
have failed to distinguish between free and bound 20S proteasomes
[28,29]. A recent study has further investigated the modulation of 20S
proteasome activity and/or localization, demonstrating that 20S
proteasomes associated with PA28γ complexes are localized to
nuclear speckles and implicated in the intranuclear trafﬁcking of SR
proteins [30]. Additional research of this nature will be needed to
more fully characterize the precise cellular functions of these alternate
proteasome-regulator complexes, as well as to decipher the speciﬁc
physiological signals that regulate proteasome-regulator composition.
4. UPS and PD
The evaluation of human postmortem brain tissue has provided a
considerable amount of evidence implicating proteasomal dysfunc-
tion in PD pathogenesis. Using enzymatic assays to measure
proteasome activity, a signiﬁcant decrement in chymotrypsin-like,trypsin-like, and caspase-like activity was detected in the SN of PD
patients when compared to age-matched controls [31–34]. However,
no deﬁcits in proteasomal activity were detected in extranigral
regions, and Furukawa and colleagues actually observed an increase
in proteasomal activity in unaffected regions, speciﬁcally the cerebral
cortex and striatum, of PD patients compared to age-matched controls
[31]. In line with these ﬁndings, immunoblotting and histological
techniques revealed a decrease in subunits of the 20S proteasome and
the PA700/19S complex in the SN of PD patients, while protein levels
where unchanged or increased in extranigral brain regions [31,32,35].
In addition, the accumulation of ubiquitinated proteins, heat shock
proteins/chaperones, and components of the UPS within LBs provides
further support for a central role of UPS dysfunction in the
etiopathogenesis of PD [36–41]. However, these ﬁndings must be
interpreted with caution, as the above-mentioned studies do not take
into account neuronal loss, nor do they identify the affected cell type
(i.e. neuronal vs glial).
The link between proteasomal inhibition and the pathogenesis of
PD was further solidiﬁed by the demonstration that treatment with
the proteasomal inhibitor lactacystin dose-dependently leads to the
degeneration and the formation of synuclein and ubiquitin-positive
inclusions in rat ventral mesencephalic primary neurons [42,43]. In
vivo, McNaught and colleagues reveal that systemic administration of
proteasomal inhibitors in Sprague–Dawley rats produced both a
behavioral and pathological phenotype reminiscent of PD [44]. In
addition to the progressive nature of the motor impairment exhibited
by treated rats, administration of dopamine agonists alleviated
behavioral symptoms. Postmortem analysis revealed loss of dopamine
in the striatum, as well as neuronal loss and the presence of
eosinophilic, synuclein/ubiquitin-positive inclusions in remaining
neurons of the SN [44,45]. However, this model has since been
viewedwith great scrutiny due to the inability of different laboratories
to replicate these ﬁndings [46–49]. Although two additional labora-
tories were able to replicate dopaminergic cell loss following systemic
administration of proteasome inhibitors, only Zeng and associates
detected the presence of synuclein aggregates in the SN, while neither
group observed a progressive motor impairment [50,51]. It is
hypothesized that extraneous variables due to differences in formula-
tion of the proteasomal inhibitors, strain background differences in
treated rats and mice, as well as environmental factors, could account
for this variability in ﬁndings. However, the extensive variability in
consequences of in vivo proteasomal inhibition casts signiﬁcant doubt
on the utility of this approach as an accurate model of PD.
Despite the failure of in vivo administration of proteasome
inhibitors to consistently produce a parkinsonian phenotype, an
exciting new report from Bedford and associates provides striking
evidence establishing a link between 26S proteasome dysfunction and
the development of α-synuclein neuropathology [52]. In this study,
Bedford and colleagues develop and characterize a novel mouse
model expressing a conditional deletion of the Rpt2/PSMC1 subunit,
an ATPase of the 19S regulatory complex, spatially restricted to
neurons of the forebrain, or a secondmodel inwhich the Rpt2/PSMC1
subunit is ablated in TH-positive neurons. As the Rpt2/PSMC1 subunit
is required for both the assembly and activity of the 26S proteasome,
conditional knockdown of Rpt2/PSMC1 expression produced a
speciﬁc impairment of 26S proteasome activity, while 20S proteasome
activity was unaffected. Intriguingly, synuclein and ubiquitin-positive
inclusions resembling LBs were observed in either neurons of the
forebrain region or the nigrostriatal pathway, with the localization of
pathology coincident with Rpt2/PSMC1 knockdown, and thus 26S
dysfunction [52]. Although no motor impairment or parkinsonian
phenotype is reported in this study, genetic ablation of Rpt2/PSMC1 in
the forebrain did produce a learning deﬁcit, as well as progressive
neurodegeneration of forebrain regions. As restriction of Rpt2/PSMC1
knockdown to TH-positive neurons is particularly relevant to PD
pathology, it is disappointing that autonomic dysfunction leading to
Fig. 1. A putative mechanism by which the UPS acts downstream of BDNF/TrkB
signaling to ultimately regulate α-synuclein aggregation. According to this hypothetical
model, synuclein-mediated inhibition of the UPS interferes with stimulatory effects of
BDNF on synaptic activity, as well as the inhibitory inﬂuence of BDNF signaling on
parkin cleavage and inactivation by the Fas/FADD death receptor pathway.
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assessment of these mice [52].
The relationship between UPS impairment and sporadic PD has
also been strengthened by a number of in vitro studies demonstrating
a decrease in proteasome activity following exposure to pesticides and
environmental toxins linked to PD, including rotenone, paraquat, and
maneb [53–55]. Consistent with in vitro ﬁndings, the in vivo
administration of rotenone led to a reduction in proteasome activity
speciﬁcally in the ventral midbrain of rats [53]. Intriguingly, utilization
of osmotic minipumps to continually deliver the PD-linked toxin
MPTP tomice for one month produced a PD-like phenotype, including
depletion of striatal dopamine levels and neuronal loss in both the SN
and locus coeruleus, which was accompanied by the formation of α-
synuclein and ubiquitin-positive inclusions [56]. These mice also
exhibited a decrease in proteolytic activity of the proteasome in
striatal extracts as assessed by enzymatic assays, as well as a
progressive decline in motor activity that was rescued by administra-
tion of dopamine agonists. Surprisingly, when experiments were
replicated in mice lacking α-synuclein, neuronal loss, behavioral
impairments, and the formation of ubiquitin-positive inclusions were
alleviated [56]. Perhaps most telling was the demonstration that
impairments in proteolytic activity following MPTP administration
were also alleviated in the absence of α-synuclein, suggesting that α-
synuclein exacerbates the deleterious effects of PD-linked environ-
mental toxins on UPS function. Furthermore, these ﬁndings imply that
α-synuclein, and possibly UPS dysfunction, is critically involved in the
manifestation of a PD phenotype.
The demonstration that MPTP treatment alters proteasomal
activity has also been replicated in non-human primates [57].
Speciﬁcally, both proteolytic activity and expression of proteasomal
subunits is decreased in extracts from the SN of MPTP-treated
marmoset monkeys similarly to alterations observed in PD patients,
though synuclein pathology, neuronal loss, and behavioral impair-
ments were not assessed in this cohort of monkeys. However, an
earlier study performed by Kowall and colleagues revealed an
initiation of α-synuclein aggregation upon MPTP treatment in
baboons, with regrettably no evaluation of either proteasomal activity
or expression performed in this study [58]. Thus the precise
involvement of α-synuclein pathology and UPS impairment in
MPTP-linked PD and parkinsonism remains to be more conclusively
established.
5. Genetic links to PD and association with UPS
Although the majority of PD cases are sporadic, a number of
genetic loci have been identiﬁed and linked to the inheritance of
familial PD. The relationship between these genes is still presently
unclear, as is the connection between familial-linked genes and the
etiology of idiopathic PD. However, the clinical and pathophysiological
similarities between familial and idiopathic forms of PD suggest they
may share a common pathogenic mechanism [59]. Given the
considerable evidence implicating a central role for UPS impairment
in the development and progression of sporadic PD, it is intriguing
that a number of genetic mutations linked to PD are also involved in
the regulation of UPS function. The direct and indirect relationship(s)
between these PD-linked genes and modulation of the UPS will be
discussed below.
5.1. α-Synuclein
α-Synuclein is a natively unfolded presynaptic protein initially
cloned from the electric lobe of Torpedo californica [60]. Although the
function of α-synuclein is still unknown, it adopts an α-helical
structure upon binding to phospholipids [61], and has been shown to
modulate synaptic transmission through the regulation of synaptic
vesicle recycling and the compartmentalization of neurotransmitters[62–66]. In addition, Fortin and colleagues have demonstrated that
lipid rafts are required for the presynaptic localization of α-synuclein,
and further that both synaptic localization and membrane association
of α-synuclein are modulated by neuronal activity [67,68]. These
ﬁndings, in concert with evidence that BDNF-TrkB signaling acts
upstream of the UPS to regulate the expression level of key synaptic
proteins in response to neuronal activity, could have signiﬁcant
implications for PD pathogenesis [69]. In particular, given the
suspected link between PD and UPS dysfunction, a local impairment
of the UPS within the synapse theoretically could promote the
accumulation of ubiquitinated proteins irrespective of BDNF-TrkB
signaling, thereby preventing BDNF-TrkB-mediated synaptic remodel-
ing and leading to a decrease in neuronal activity. A reduction in
neuronal activity would not only decrease BDNF expression and
synaptic release [70–73], but based on the ﬁndings of Fortin and
associates, would also be expected to increase the amount of
membrane-bound α-synuclein localized to the synapse [67,68].
Taking into consideration the higher propensity of membrane-
bound synuclein to aggregate and seed the aggregation of the more
abundant, cytosolic form of α-synuclein [74], a decrease in neuronal
activity and subsequent increase in membrane-bound synuclein,
further exacerbated by a decrement in BDNF expression, could
effectively establish a pathogenic, positive-feedback mechanism
linking neuronal activity and UPS functionwith synuclein aggregation
(Fig. 1). In addition, the demonstration by Dluzen and colleagues that
targeted deletion of a BDNF allele potentiates the age-dependent
decline in nigrostriatal dopaminergic function in mice provides a
potential explanation for susceptibility of the nigrostriatal dopamine
system to synuclein pathology with aging [75].
5.1.1. Modulation of aggregation potential of α-synuclein
The precipitating basis of α-synuclein aggregation in synucleino-
pathies is controversial, though broadly speculated to arise from an
increase in α-synuclein protein expression (either through gene
triplication or altered transcriptional or translational activities),
excessive posttranslational modiﬁcations (including phosphorylation,
ubiquitination, oxidation, nitration, truncation), or through increased
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propensity of α-synuclein to ﬁbrillize [76–88]. In addition, the
negatively-charged C-terminus of α-synuclein, which has also been
shown to bind dopamine derivatives [89], appears to act as a negative
regulator of aggregation [82,84,90]. Thus it is highly likely that
posttranslational modiﬁcations to this region, including phosphoryla-
tion, ubiquitination, oxidation, nitration, and truncation [77,78,91],
inﬂuence the propensity of α-synuclein to aggregate.
Critical evaluation of the various α-synuclein species observed in
LBs demonstrates that α-synuclein is selectively and extensively
phosphorylated at Ser129 (pSer129) in these lesions, and further
that this is the predominant modiﬁcation of α-synuclein in LBs
[77,92,93]. In addition to phosphorylation at Ser129, α-synuclein in
LBs is also N-terminally acetylated and ubiquitinated, as well as C-
terminally truncated [92]. Given that both normal and diseased
brains contain trace amounts of soluble α-synuclein pSer129, as well
as species that are truncated at Asp119, it is believed these forms of
α-synuclein are generated through normal metabolism [92]. How-
ever, in postmortem brain tissue from synucleinopathy patients, the
majority of pSer129 is detected in insoluble fractions. Because the
main ubiquitinated α-synuclein species found in LBs is also pSer129
α-synuclein, it is hypothesized that an excess of pSer129 may
actually serve as the priming event which ultimately culminates in
the formation of LBs. Anderson and colleagues further posit that
pSer129 may serve as a signal for proteolysis, supported by their
observation that all α-synuclein species truncated at Tyr133 were
also pSer129 [92].
Given the potential ramiﬁcations ofmodulating phosphorylation at
Ser129, a number of laboratories have investigated prospective kinases
that phosphorylate this site, leading to the identiﬁcation of casein
kinase 1 and 2, as well as G-protein coupled receptor kinases [94–97].
In support of a pathogenic role of pSer129, overexpression of α-
synuclein and GRK5 (G-protein coupled receptor kinase 5), which
colocalize in LBs, promotes GRK5-mediated phosphorylation at Ser129
and leads to the formation of soluble oligomers and aggregates of α-
synuclein [94]. In addition, pSer129 has also been shown to increase
the propensity of α-synuclein to aggregate following exposure to
mitochondrial or oxidative stressors [98,99]. In contrast, Paleologou
and colleagues demonstrate that in vitro phosphorylation of α-
synuclein at Ser129 inhibits ﬁbrillogenesis, but does not perturb the
overall conformation of synuclein and its ability to adopt α-helical
conformations upon membrane-binding to synthetic vesicles [96].
Perhaps most importantly, Paleologou and associates reveal a
discrepancy in the structural and aggregation properties of α-
synuclein phosphorylated in vitro and the phosphorylation mimics
S129E, S129D [96], which could explain the inconsistent ﬁndings
evaluating the consequences of α-synuclein phosphorylation. Speci-
ﬁcally, Gorbatyuk and coworkers report that the phosphorylation
mimic S129D is protective against dopaminergic cell loss when
injected into the SN of rats, while Chen and Feany demonstrate an
enhanced toxicity associated with α-synuclein phosphorylation in
Drosophila [76,100]. However, Chen and Feany substantiate their
ﬁndings by demonstrating that both the phosphomimetic and
kinase-phosphorylated wild-type synuclein produce a similar pheno-
type [76]. In addition, Chen and Feany observe an inverse correlation
between α-synuclein phosphorylation and aggregation potential,
which is consistent with the report by Paleologou and colleagues
[76,96].
In addition to phosphorylation, α-synuclein present in LBs is also
ubiquitinated [77,92]. Recently, the RING-type E3 ubiquitin ligase SIAH
(seven in absentia homolog) has been shown to interact with and
monoubiquitinate α-synuclein in vitro and in vivo, thereby increasing
the propensity of α-synuclein to aggregate [101,102]. Although there
was no difference in the ability of SIAH tomonoubiquitinate wild-type
ormutantα-synuclein, signiﬁcantlymore inclusions were observed in
cells overexpressing the A53Tmutant [102]. This suggests that despitean increased tendency of α-synuclein to aggregate upon SIAH-
mediated monoubiquitination, additional factors further modulate
this tendency. In addition, ubiquitination of α-synuclein by SIAH
increases cell susceptibility to proteasome impairment and promotes
apoptotic cell death, suggesting that SIAH activity plays a crucial role
in determining the toxicity of α-synuclein under conditions of
proteasome dysfunction [101,102].
An additional substrate of SIAH, synphilin-1, is a synuclein-
interacting protein that colocalizes with α-synuclein in LBs [103–105].
Intriguingly, overexpression of synphilin-1 inhibits proteasomal func-
tion, and also leads to the formation of ubiquitinated cytoplasmic
inclusions positive for both synphilin-1 and α-synuclein [103,105].
SIAH-mediated ubiquitination has been shown to target synphilin-1 for
degradation by the UPS [104], though phosphorylation of synphilin-1
on serine556byGSK3βprevents SIAH-mediatedubiquitination and the
subsequent degradation of synphilin-1 [106]. Prevention of this
phosphorylation by either GSK3β inhibition or mutation of the
phospho-residue (S556A) promotes the formationof synphilin-positive
ubiquitinated inclusions that colocalize with increased expression of
the UPS reporter, GFPμ, which may indicate that phosphorylation
determines inhibitory potential of synphilin-1 on proteasome activity
[106]. However, the effect of synphilin-1 phosphorylation or ubiquiti-
nation on ability to bind and interact with α-synuclein could be a
confounding variable in these studies, in particular with the discovery
that α-synuclein is also a substrate for SIAH [101,102].
Although Anderson and colleagues state that truncated α-
synuclein does not appear to be highly enriched in LBs in comparison
to pSer129 α-synuclein [92], earlier studies report that approximately
15% of α-synuclein in LBs is truncated [34,107,108]. Based on these
earlier ﬁndings, as well as the demonstration that truncated humanα-
synuclein (amino acid residues 1–120) ﬁbrillizes faster than either
wild-type or mutant protein [84,90,109], a mouse model was
generated expressing truncated human α-synuclein (1–120) on a
synuclein null background [88]. Surprisingly, synuclein-positive
inclusions were detected in dopaminergic neurons in the substantia
nigra and olfactory bulb, and decrements in striatal dopamine levels
correlated with motor impairment [88]. The susceptibility of dopa-
minergic neurons to synuclein toxicity could be explained by the
observation that dopamine has been shown to inhibit α-synuclein
ﬁbrillization in vitro, leading to the proposal that either dopamine or
its metabolites kinetically stabilize oligomeric α-synuclein intermedi-
ates [89,110–113]. This hypothesis is supported by a signiﬁcantly
higher α-synuclein oligomer to monomer ratio in the SN compared to
cortical tissue of symptomatic A53T mice [114]. In addition, Mazzulli
and associates demonstrate that increasing catechol levels in SH-SY5Y
cells that overexpress mutant A53T α-synuclein by cotransfecting
with tyrosine hydroxylase prevents the formation of insoluble α-
synuclein aggregates and increases the concentration of soluble
oligomers [114]. As the amino acid residues 125–129 in the C-
terminus of α-synuclein have been shown to be required for catechol-
mediated inhibition of synuclein aggregation [89,115], it is interesting
that a mouse model overexpressing truncated wild-type α-synuclein
(1–120), which lacks the catechol-interaction site, develops insoluble
synuclein aggregates in dopaminergic neurons [88].
Alternatively, a decrease in degradation of the α-synuclein protein
could serve as the basis for pathogenic overexpression. To characterize
the degradative pathway for α-synuclein, Bennett and colleagues
demonstrate that both wild-type and mutant A53T α-synuclein are
substrates of the proteasome in SH-SY5Y neuroblastoma cells [116].
However, Ancolio and associates were unable to observe proteasome-
mediated degradation of either wild-type or mutant synuclein in
HEK293 cells, though an effect of calpain inhibition on synuclein
expression was also not detected [117], despite the fact that a number
of investigators have observed calpain-mediated cleavage of α-
synuclein [83,118,119]. Given the natively unfolded structure of α-
synuclein, it has now been shown that wild-type α-synuclein can be
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[21,120,121]. On the other hand, A53T α-synuclein exhibits a 50%
longer half-life compared to wild-type, suggesting mutant A53T α-
synuclein is not degraded as efﬁciently by the proteasome [116]. In
addition, the metal-catalyzed oxidation of α-synuclein enhanced the
formation of oligomeric and protoﬁbrillar forms, simultaneously
preventing mature ﬁbril formation [120]. Although monomeric α-
synuclein was degraded in a proteasome-dependent manner, the
degradation of oxidized oligomeric α-synuclein was completely
prevented [120].
Given that α-synuclein adopts an α-helical conformation upon
binding to membranes, and further that natively unfolded α-
synuclein has been reported to be a substrate for the proteasome
[21,120,121], Liu and colleagues demonstrate that only unbound,
cytosolic α-synuclein is a substrate for the proteasome, while
membrane-bound, α-helical α-synuclein is not degraded by the
proteasome [122]. This suggests that loss of vesicular or membrane-
binding ability due to mutation [123] or oxidative damage [81,124]
would enhance 20S-mediated cleavage of α-synuclein, increasing the
generation of truncated fragments. In vitro, proteasome-mediated
cleavage of α-synuclein yielded three predominant fragments,
including 1–119, 1–110, and 1–83, which all adopted a random coil
conformation indistinguishable from the full-length protein [122].
Cotransfection of full-length and truncated variants of α-synuclein in
SH-SY5Y cells increased cell vulnerability to oxidative stress, and
induced aggregation of full-length protein, with A53T mutants
aggregating more rapidly than parallel combinations of wild-type
protein [122]. Thus Liu and associates speculate that proteolytic
activity of the proteasome produces highly amyloidogenic α-synu-
clein fragments via partial degradation of cytosolic protein, which
induces the aggregation of full-lengthα-synuclein [122]. These hybrid
aggregates further impair proteasome activity, exacerbating the
accumulation of truncated and full-length α-synuclein deposits,
creating a vicious cycle of cytotoxicity.
5.1.2. Evaluation of α-synuclein-mediated UPS impairment
A direct inhibitory effect of synuclein on UPS activity has been
reported, though the effects of overexpression, mutation, aggregation,
and posttranslational modiﬁcations of the synuclein protein on
proteasome function are still under debate due to conﬂicting reports,
most likely resultant from methodological differences in sample
preparation and analysis. Tanaka and colleagues demonstrated an
impairment in proteasome activity in dopaminergic PC12 cells
following the overexpression of wild-type α-synuclein, with an
even greater inhibitory effect observed following overexpression of
mutant A30P α-synuclein [125]. In contrast, Martin-Clemente and
associates failed to detect an alteration in proteasome activity in stably
transfected PC12 cells with EYFP-tagged α-synuclein constructs,
including wild-type, as well as the PD-linked mutants A30P and
A53T [126]. However, the authors fail to demonstrate a signiﬁcant
increase in exogenous synuclein expression over basal levels, and
instead report signiﬁcant overexpression of synuclein based on EYFP
immunoreactivity, which is not a valid comparison [126].
An inhibitory effect on proteolytic activity mediated by over-
expressed wild-type α-synuclein has since been replicated in
dopaminergic N27 cells and MG63 (osteosarcoma) cells [127,128],
but not in CHO (ovarian) cells [129], whichmay indicate that effects of
α-synuclein are cell-type speciﬁc. In support of this, Petrucelli and
associates observed proteasomal impairment following the over-
expression of mutant A53T and A30P α-synuclein, but not wild-type,
in M17 neuroblastoma cells [130]. In addition, Chen and colleagues
observed an inhibition of proteasome-mediated degradation of short-
lived proteins in yeast cells overexpressing wild-type α-synuclein,
with an even greater impairment exhibited by cells expressingmutant
A30P α-synuclein [131]. Although there was no change in proteolytic
activity of immunoprecipitated 20S proteasomes from cells over-expressing either wild-type or A30P α-synuclein, proteasome subunit
composition and interaction with regulatory proteins was signiﬁ-
cantly altered by both wild-type and A30P α-synuclein overexpres-
sion [131]. These results may indicate that α-synuclein does not
directly inhibit the active/catalytic site of the proteasome, but instead
exerts an inhibitory effect through modulation of proteasome activity.
A recent report from the Sudhof laboratory supports this hypothesis,
demonstrating a dramatic alteration in the expression of proteasomal
subunits in spinal cord from symptomatic A30P α-synuclein mice
[132]. However, there was signiﬁcant neuronal loss and gliosis
observed in the spinal cord from symptomatic A30P mice, and as
biochemical assessment of proteasome subunit expression does not
differentiate between cell types, it is most likely that neuronal loss
coupled with the signiﬁcant increase in activated glia accounts for the
changes in proteasomal subunit expression. In addition, a recent
report by Emmanouilidou and coworkers detected a signiﬁcant
impairment in proteasome activity in the cortex of A53T α-synuclein
mice, though expression of proteasomal subunits remained
unchanged [133].
The effect of α-synuclein aggregation on proteasome activity has
also been evaluated, with groups consistently reporting a greater
proteasomal impairment in the presence of aggregated compared to
monomeric α-synuclein [134–136]. Although both monomeric and
aggregated α-synuclein have been shown to bind the S6′/TBP1 (Tat
binding protein 1) subunit of the 19S/PA700 proteasome complex
[135,137], only aggregated α-synuclein inhibits ubiquitin-dependent
and independent 26S proteasomal activity [135]. Zhang and
colleagues have also demonstrated that α-synuclein protoﬁbrils
inhibit the ubiquitin-independent degradation of unstructured
proteins by the 26S proteasome, though monomers and dimers
have no effect on the proteolysis of these substrates [136]. In
contrast, ubiquitin-dependent 26S proteasome activity is slightly
inhibited by monomeric and dimeric α-synuclein, while protoﬁ-
brillar α-synuclein potently inhibits the degradation of polyubiqui-
tinated proteins. Given that α-synuclein protoﬁbrils bind the 19S/
PA700 regulatory complex of the 26S proteasome, as well as p21 (an
unstructured proteasomal substrate) and K48-linked polyubiquitin
chains, it is proposed that α-synuclein protoﬁbrils inhibit 26S
proteasome activity by interfering with substrate translocation into
the proteasome core, achieved through direct interactions with the
proteasome, as well as through the sequestration of proteasomal
substrates [133,136].
Given that, α-synuclein, Aβ, polyglutamine proteins, prion
protein, and other amyloidogenic proteins adopt a similar structure
upon oligomerization, it is hypothesized that these proteins also
share similar pathogenic effects [138]. In agreement with this,
impaired proteasomal function is observed in parallel with the ﬁrst
appearance of soluble Aβ oligomers in the triple transgenic mouse
model of AD (3x Tg-AD), while proteasome activity is restored at a
time point when soluble Aβ oligomers are converted into insoluble
aggregates [139]. This suggests that soluble oligomeric Aβ species,
and not the monomeric or ﬁbrillar form of Aβ, inhibits proteasomal
activity [139]. UPS impairment has also been observed in cell culture
and animal models overexpressing mutant huntingtin protein
[129,140–144], and consistent with data proposing a protective
effect of aggregation due to sequestration of toxic species, treatment
with a compound that increases inclusion formation prevents
huntingtin-mediated proteasome inhibition [129]. In addition, the
abnormal prion conformer (PrPsc) inhibits the 26S proteasome in
vitro, while either preincubation with an oligomer antibody or heat
denaturation of PrPsc alleviated this inhibitory effect, indicating a
speciﬁc conformation of an oligomeric PrPsc intermediate mediates
the proteasomal inhibitory effect [145]. Proteasome activity was also
signiﬁcantly decreased in cells exposed to prion-infected mouse
brain homogenates, as well as in brain regions exhibiting signiﬁcant
prion neuropathology in mice infected with PrPsc, establishing a
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ciated with prion infection [145].
Based upon the above ﬁndings, as well as the lack of direct in vivo
evidence of a link between α-synuclein pathology and UPS dysfunc-
tion, our laboratory has generated a transgenic mouse model
expressing the proteasomal reporter GFPμ [140]. In vitro, expression
of GFPμ is dose-dependently increased in the presence of the
proteasome inhibitor MG132, illustrating the sensitivity of GFPμ to
perturbations in proteasomal function [130]. In addition, cotransfec-
tion of GFPμ and mutant A53T or A30P α-synuclein leads to an
upregulation of GFPμ, demonstrating the inhibitory effects of mutant
α-synuclein on UPS activity [130]. Thus we are crossing GFPμ
transgenic mice with mutant A53T α-synuclein mice [146], which
will allow us to monitor effects of α-synuclein pathology on UPS
function in vivo by evaluating bigenic mice at various time points. This
model will also allow us to determine selective vulnerability of
speciﬁc cell populations to synuclein-mediated perturbations in
proteasome activity. Ultimately, following the initial characterization
of GFPμ×A53T mice, it is anticipated this model can be utilized to
develop novel therapeutic approaches to preclude inhibitory effects of
α-synuclein on UPS function.
5.2. Parkin
Mutations in the E3 ubiquitin ligase parkin cause early onset PD
with an autosomal recessive inheritance pattern [147,148]. Although
various mutations in the parkin gene have been linked to PD,
including missense, nonsense, frameshift point mutations, exon
deletions and duplications, to date there is no noticeable variation
in clinical manifestation between the different mutations [148,149].
Neurodegenerative changes are also relatively similar in sporadic PD
and early onset PD caused by parkin mutations, with both types
exhibiting neuronal loss and gliosis that is primarily restricted to the
brainstem. However, LBs are not typically observed in patients with
parkin-linked PD, though the signiﬁcance of this observation is still
under speculation [150–153].
Despite the lack of LB formation, PD patientswith parkinmutations
do showan accumulation of parkin substrates [154–156], whichwould
suggest that α-synuclein is not a substrate for parkin. However, α-
synuclein and parkin do colocalize in LBs [41]. In addition, under basal
conditions, parkin and α-synuclein have been shown to associate and
colocalize to the cytosol and neuritic processes [157,158]. Inhibition of
proteasomeactivity in cells coexpressingα-synuclein andparkin led to
a decrease in parkin solubility accompanied by the formation of
inclusions positive for bothα-synuclein and parkin, while knockdown
of α-synuclein increased parkin solubility under conditions of
proteasomal impairment [158]. Given that proteasome inhibition
also increases parkin expression [158], and that autoubiquitination of
parkin promotes its degradation by the proteasome [159–162], it is
possible that the level of expression and/or ubiquitination of parkin
may regulate its association with α-synuclein. These alterations in
parkin expression and/or ubiquitination may be further exacerbated
by the accumulation of α-synuclein, which could contribute to the
pathogenesis of PD by promoting a decrease in parkin solubility and in
turn, compromising neural function. Mutations in α-synuclein have
also been shown to more efﬁciently stimulate parkin aggregation in C.
elegans [163] and neuroblastoma cells [158]. Thus it is hypothesized
that mutations associated with familial parkinsonism in combination
with exposure to cellular stressors, including proteolytic or oxidative
stress, might facilitate the pathological interactions between α-
synuclein and parkin.
The effects of PD-linked mutations in parkin also appear to
universally result from alterations in parkin solubility and intracellular
localization, possibly due to misfolding of the mutant protein
[54,164,165]. Wang and colleagues demonstrate that exposure to
PD-linked environmental toxins, as well as oxidative or proteolyticstressors, promotes the depletion of soluble, functional parkin, which
correlates with reduced proteasomal activity and increased cell death
[54]. In addition, Chung and associates observed S-nitrosylated parkin
in both mice exposed to MPTP and human postmortem brain tissue
from PD and diffuse LBD patients, which was negatively correlated
with parkin function [166]. Given that parkin has also been shown to
become increasingly more insoluble with age [167], and that risk for
PD increases with age, it would appear that loss of functional parkin is
a major, pathogenic mechanism. In particular taking into considera-
tion that parkin has been shown to exert a signiﬁcant neuroprotective
effect against various toxic insults, including manganese-induced cell
death,α-synuclein toxicity, proteasomal dysfunction, Pael-R and P38/
JTv-1 accumulation, kainate-induced excitotoxicity, mitochondrial-
dependent apoptosis, MPP+/rotenone-induced cell death, ER stress,
and dopamine-mediated toxicity [54,130,154,155,168–175].
In Drosophila, deletion of the parkin gene leads to the progressive
degeneration of dopaminergic neurons in the central nervous system
(CNS), a phenotype which is exacerbated by loss of glutathione-S-
transferase [176], a gene which is actually upregulated by the PD-
linked gene DJ-1 in response to oxidative stress [177]. Conﬁrming the
speciﬁcity of this effect, the neurodegenerative phenotype in parkin
mutants was suppressed by overexpression of glutathione-S-transfer-
ase [176], which suggests that loss of functional parkin increases
sensitivity to oxidative stress. However, given that Drosophila do not
express endogenous α-synuclein or Pael-R, it may not be possible to
fully appreciate the consequences of alterations in parkin function in
this model.
The selective vulnerability of dopaminergic neurons in PD could
potentially be explained by the demonstration that dopamine can
covalently modify parkin in vitro, decreasing parkin solubility and E3
ligase activity [178]. In support of these in vitro results, LaVoie and
colleagues also observed a decrease in parkin solubility in PD patients,
as well as the presence of catechol-modiﬁed parkin in the SN [178]. In
addition, embryonic dopaminergic neurons are particularly sensitive
to deprivation of the growth factors GDNF or BDNF, activating a novel,
apoptotic pathway in their absence [179]. Cell death was shown to be
independent of mitochondria, though caspase activation was still
required, as treatment with a caspase inhibitor, and more speciﬁcally
inhibition of caspase 8, prevented cell death mediated by GDNF/BDNF
withdrawal. Yu and coworkers were also able to suppress cell death
induced by GDNF/BDNF deprivation by inhibiting Fas or FADD (Fas-
associated protein with death domain), which is an adaptor required
for Fas-mediated activation of caspase 8, thus implicating the death
receptor pathway in this phenomenon [179]. Intriguingly, Kahns and
associates demonstrate that while caspases 1, 3, and 8 cleave parkin,
both caspase 1 and 8 directly cleave parkin without requiring
activation of the effector caspase 3, suggesting that death receptor
activation and inﬂammatory stress promote the cleavage and
inactivation of parkin [180]. Thus given the suspected link between
depletion of neurotrophic factors and PD pathogenesis [181–183], in
addition to the detection of cleaved parkin fragments in LBs isolated
from the SN of PD patients [41,184], it is possible that caspase 8-
mediated cleavage and resultant inactivation of parkin may play a
pathogenic role in PD progression, and additionally establishes a
potential mechanism for the selective vulnerability of dopaminergic
neurons in PD (Fig. 1).
5.3. DJ-1
Mutations in DJ-1, an antioxidant, redox-sensitive molecular
chaperone [185–188], are linked to rare forms of autosomal recessive,
early-onset PD [189,190]. PD-linked mutations in DJ-1 include
missense, truncation, and splice site mutations, as well as large
deletions, suggesting that loss of DJ-1 function leads to neurodegen-
eration [190–192]. Of particular relevance to PD neuropathology, DJ-1
inhibits the oligomerization and toxicity of mutant A53T α-synuclein,
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synuclein [177,193]. Knockdown or deletion of DJ-1 also increases
susceptibility to proteasome inhibition in vitro [194,195]. Through the
modulation of glutamate cysteine ligase expression, the rate-limiting
enzyme in glutathione synthesis, wild-type DJ-1, but not the PD-
linked mutant L166P, is protective against oxidative stress, while
blocking glutathione synthesis abolishes the protective effect of DJ-1
[177]. Loss of DJ-1 function is further implicated in PD pathogenesis by
the observation that glutathione levels are decreased in the SN in early
stages of PD [196], as well as the demonstration that depletion of
glutathione leads to an age-related neurodegeneration of the
nigrostriatal pathway by oxidation-dependent inhibition ofmitochon-
drial complex I [197–200].
Recently, a surprising link between expression levels of protea-
some subunits and DJ-1 was identiﬁed. In nontransgenic mice,
treatment with antioxidants enhances the expression of 20S and 19S
proteasome subunits, as well as proteasome activity [201]. However,
no induction of proteasome activity or expression of proteasome
subunits is observed in mice lacking the transcription factor Nrf2
(nuclear factor erythroid 2-related factor). Further, activity of the
promoter regulating expression of the 20S β5 subunit, PSMB5, is
increased with either overexpression of Nrf2 or exposure to
antioxidants [201]. Given that Nrf2 is a component of the transcription
complex that binds to the cis-acting element ARE (antioxidant
response element), which regulates the expression of proteins that
are protective against oxidative stress (e.g. glutathione S-transferases,
glutamyl cysteine ligase, and NADPH quinone oxidoreductase) [202–
205], the proximal promoter of PSMB5 was evaluated and an ARE
subsequently identiﬁed [201]. Under normal conditions, Nrf2 is
sequestered in the cytosol by the actin-binding protein Keap1 [206].
Exposure to antioxidants causes the dissociation of Nrf2 from Keap1,
allowing for the nuclear translocation of Nrf2 and transcription of ARE
genes. Amazingly, DJ-1 actually binds and stabilizes Nrf2, preventing
the interaction with Keap1 and decreasing ubiquitination and
subsequent proteasome-dependent degradation of Nrf2 [207,208]. In
the absence of DJ-1, Nrf2 is unstable and rapidly degraded, leading to a
decrease in transcription of ARE genes [207].
These ﬁndings could explain the dopaminergic cell loss and motor
dysfunction observed in DJ-1 deﬁcient mice upon exposure to the PD-
associated herbicide paraquat [209]. Following treatment with
paraquat, Yang and coworkers report a decrease in Nrf2, as well as
the 19S ATPase Rpt6 and 20S β5 subunits in the ventral midbrain of DJ-
1 knockout mice, while no pathological abnormalities were detected
in wild-type mice treated with paraquat [209]. In addition, protea-
some activity in the ventral midbrain was decreased by 30% in DJ-1
deﬁcient mice treated with paraquat when compared to the saline-
treated group, which was accompanied by an increase in protein
ubiquitination. Thus DJ-1 appears to be crucial for the survival of
dopaminergic neurons, in particular under conditions of cellular
stress.
5.4. LRRK2 (leucine-rich repeat kinase 2)
LRRK2, which is detected in both LBs and granular α-synuclein
deposits believed to represent LB precursors [210,211], was originally
linked to the PARK8 locus in a large Japanese family [212]. This linkage
was subsequently questioned by the discovery Family SK, carriers of
the most common LRRK2 mutation (G2019S) [213], which clinically
present with a slowly progressive parkinsonism, though no LBs or
synuclein pathology was observed in any brain region evaluated upon
autopsy [214]. Further adding to the complexity, a recent case history
details a patient carrying the G2019S LRRK2mutationwith a history of
slowly-progressive PD, though histological assessment revealed nigral
degeneration in the absence of both α-synuclein and tau pathology
[215]. However, numerous Marinesco bodies, which are spherical
eosinophilic ubiquitin-positive intranuclear inclusions, were observedin both the SN and locus coeruleus [215]. Given that proteasome
inhibition in vitro can lead to aberrations in ubiquitin immunoreac-
tivity reminiscent of Marinesco body formation [216], it is possible
that mutations in LRRK2 may disrupt UPS function, though an
explanation for the pleomorphic pathology associated with LRRK2
mutations is still unknown.
A more direct link between LRRK2 and the UPS was established by
Smith and associates in their discovery of an interaction between
LRRK2 and parkin, but not DJ-1, α-synuclein, or tau, consistent with
observations by Rajput and coworkers [214,217]. Interestingly, over-
expression of LRRK2 led to the formation of inclusions in a small
fraction of cells, which was exacerbated by the coexpression of parkin
[217]. Although LRRK2 mutants displayed a similar cellular localiza-
tion, ability to associate with parkin, and tendency to aggregate in
comparison to the wild-type protein, all mutants evaluated (R1441C,
Y1699C, G2019S) increased cell death, which could not be prevented
by the coexpression of parkin [217]. As LRRK2 activity increases the
autoubiquitination of parkin [217], thus promoting the proteasome-
mediated degradation of parkin [159–162], and mutations in LRRK2
are predicted to increase kinase activity [218,219], it is possible that
toxicity attributed to LRRK2mutations could result from the abnormal
modulation of parkin levels and/or activity. In addition, both wild-
type and mutant LRRK2 were recently shown to interact with heat
shock protein 90 (hsp90), and dissociation of the LRRK2-hsp90
complex promotes the UPS-mediated degradation of LRRK2 [219,220],
suggesting that proteasome dysfunction could also lead to an increase
in LRRK2 expression.
5.5. PINK1 (PTEN-induced putative kinase 1)
PINK1, a highly conserved kinase that is localized to the inner and
outer mitochondrial membranes [221–224], has been identiﬁed as the
gene locus for PARK6-linked PD, which is characterized by an earlier
age of onset than sporadic PD [224]. The most common PD-associated
mutation in PINK1 (C1366T) decreases mRNA transcript levels by 80–
90% [225], while the mutations G309D, L437P, G386A and G409V have
all been shown to reduce kinase activity in vitro [226,227]. These
ﬁndings implicate a loss of function or deﬁciency of the PINK1 protein
in PD pathogenesis, leading to the development and evaluation of
PINK1 knockout models. Intriguingly, knockout of the PINK1 gene in
Drosophila led to defects in mitochondrial morphology and degenera-
tion of dopaminergic neurons, a phenotype which was rescued by
parkin overexpression [228,229]. As deletion of the parkin gene
produced a similar phenotype [230,231] that could not likewise be
reversed by overexpression of PINK1 [228,229], and deletion of both
the parkin and PINK1 genes does not lead to an exacerbated
phenotype, it is believed that PINK1 is upstream of parkin in a
signaling cascade that regulates mitochondrial function and integrity
[228,229].
The effects of PINK1 deﬁciency on mitochondrial function and
morphology have since been replicated in both human and mouse-
derived dopaminergic neurons [232]. The deletion of PINK1 also leads
to an increased activation of the mitochondrial cell-death pathway, as
well as an elevation of ROS levels [232]. Conversely, the over-
expression of PINK1 is protective against proteasomal inhibition and
staurosporine-induced apoptosis, decreasing both cytochrome c
release and caspase 3 activation [233,234]. The overexpression of
PINK1 has also been shown to prevent abnormal depolarization of the
mitochondrial membrane in response to UPS dysfunction [235,236].
The link between PINK1 and the UPS has been further established by
Muqit and colleagues, demonstrating an enhanced cleavage and
recruitment of PINK1 to aggresomes under conditions of proteasomal
impairment, with both wild-type and mutant PINK1 displaying a
similar tendency to aggregate [222]. As PINK1 is detected in
approximately 5–10% of LBs in PD [221], the ﬁnding that PINK1
colocalizes with parkin, synphilin-1, andα-synuclein in aggresomes in
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support for a central role of UPS dysfunction in LB formation [222].
6. Conclusion
Thus it is becoming increasingly clear that genetic links to PD
either promote UPS dysfunction, or interfere with the normal
compensatory response(s) that occur to minimize toxicity from
proteasomal impairment. However, although this review evaluates
the existing data from the viewpoint that a decrement in UPS function
is central to the pathogenesis of PD, it is possible that UPS function
itself is actually modulated in response to a central impairment in an
alternate system, such as the mitochondrial or lysosomal/autophagic
pathway. Further confounding this issue, UPS impairment com-
pounded by an inefﬁcient upregulation of autophagy or mitochondrial
protein quality control mechanisms may ultimately yield a similar
phenotype to that observed by lysosomal or mitochondrial dysfunc-
tion exacerbated by proteasomal inhibition. Clariﬁcation of this issue
will assist in the identiﬁcation of speciﬁc targets that can be
modulated, as it may be possible to rescue neuronal function through
the augmentation of parallel and intersecting pathways, ultimately
enhancing the repertoire of therapeutic agents available to treat PD
and other neurodegenerative conditions characterized by abnormal
protein aggregation.
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